All In Biotech

Drug Trial Radar · NCT04730258

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML

Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 16, 2021

Primary completion

Jan 2026

Study completion Jan 2026

Sponsor

Lead sponsor
Treadwell Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jan 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • AML
  • MDS
  • CMML

Interventions

  • CFI-400945Drug

    The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.

  • AzacitidineDrug

    Azacitidine will be given at its labeled dose and schedule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent AEsTime frame: 36 months
  2. Treatment emergent changes in vital signsTime frame: 36 months
  3. Treatment emergent changes in clinical laboratory testsTime frame: 36 months
  4. Treatment emergent changes in physical examinations, ECOG performance status, electrocardiograms (ECGs), echocardiograms and cardiac troponinsTime frame: 36 months

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Norton Cancer Institute - Saint Matthews

    Louisville, Kentucky

  • New York Presbyterian Weill Cornell Medical Center

    New York, New York

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • The University of Texas MD Anderson Cancer Centre

    Houston, Texas

  • University of Alberta

    Edmonton, Alberta, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Queen Mary Hospital

    Hong Kong, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.